New Report on Revive Therapeutics (RVVTF, RVV). Ushering in Advances in Anti-Inflammatory and Antioxidant Drugs, as a Tool Against Covid.
Early Bird Gets the Worm?
Here’s a 25-page report covering almost everything you want to know about Pfizer’s (PFE) and Merck’s (MRK) Antivirals, oxidative stress, inflammation of the lungs and acute respiratory distress syndrome (ARDS).
And how Revive Therapeutics (RVVTF, RVV.CN) is using a novel approach with Antioxidants and Anti-Inflammatories to combat Covid’s most dangerous side-effect, the Cytokine Storm which can lead to ARDS, which sends patients to the ventilator and possibly death (40% chance).
We’re early but not too early, as Revive Therapeutics should have news related to its Phase III clinical trials, by this spring or coming summer.
Acute respiratory distress syndrome (ARDS) is the most common cause of death in COVID‐19 patients. And the cytokine inflammatory storm is the main driver of the severity and magnitude of ARDS.
So why hasn’t some biotech firm thought of an anti-inflammatory or antioxidant drug as a possible solution. Well, there is one we know of – Revive Therapeutics.
Under normal circumstances, cytokines help coordinate the response of your immune system to take care of infectious substances, like viruses or bacteria. The problem is that sometimes the body’s inflammatory response can get out of control, causing more harm than good.
Sometimes the body produces too many inflammatory cytokines and not enough cytokines that modulate inflammation. The inflammatory cytokines start “storming” out of control, without enough feedback from the anti-inflammatory cytokines.
Learn how Revive is repurposing a 30-year-old drug called Bucillamine which boosts one of the most powerful inflammation fighting antioxidants known to man called Glutathione. Like we said, great story. Come learn with us lol.
News coverage client, see report for disclaimer and disclosure details.